PodParley PodParley
PodParley
Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial - report from ESMO 2025 episode artwork

EPISODE · Nov 13, 2025 · 3 MIN

Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial - report from ESMO 2025

from Medical Digest & Congress Report · host Medical Congress News

Professor Maria De Santis shares her thoughts on the final analysis of the phase 3, open-Label, randomized POTOMAC trial were presented at the ESMO Congress 2025.Video: https://medicaldigest.org/scientific-contents/interview:durvalumab-combination-bcg-bcg-naive-high-risk-nmibc-final-analysis-phase-3-open-label-randomized-potomac-trial

Episode metadata supplied by the publisher feed · Published Nov 13, 2025

Embed this episode

NOW PLAYING

Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial - report from ESMO 2025

0:00 3:35

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 3 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on November 13, 2025.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!